ACM
PHAT icon

ADAR1 Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

ADAR1 Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$477K Hold
42,900
– – 0.03% 207
2025
Q4 		$712K Hold
42,900
– – 0.05% 164
2025
Q3 		$505K Sell
42,900
-20,524
-32% -$212K 0.05% 135
2025
Q2 		$608K Buy
63,424
+20,624
+48% +$114K 0.09% 107
2025
Q1 		$268K Sell
42,800
-12,600
-23% -$76.5K 0.05% 132
2024
Q4 		$450K Buy
55,400
+55,200
+27,600% +$684K 0.09% 116
2024
Q3 		$3.62K Buy
+200
New +$2.79K ﹤0.01% 264

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return